FDA approves Mylan blood pressure drug

The FDA has approved Mylan Laboratories Nebivolol for high blood pressure contingent on Mylan's submission of preclinical data and the resolution of labeling requirements. The approvable letter comes slightly more than a year after the drug company filed its NDA. Mylan representatives say the data from an ongoing preclinical study of the beta blocker should satisfy the agency. Mylan licensed Nebivolol from Janssen Pharmaceutica four years ago.

- read this story from MSN for more on the approval

ALSO: Carl Icahn has dropped his lawsuit against Richard Perry, who had supported Mylan's failed bid to buy King Pharmaceuticals. Article

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.